Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.79 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17909116 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17908626 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17909563 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17908744 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17909356 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17908657 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17909410 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17909295 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17909681 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB | |
| SCHEMBL17908732 | 1.00 | NAAA (0.79) | NAAAEPHX2HTTMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048093-B1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORP (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-10077229-B2 | Ether-containing monoester compound and use thereof | MORESCO CORPORATION (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3048093-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | Moresco Corporation (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077229-B2 | Ether-containing monoester compound and use thereof | SFN, CCNE2, HSD3B2 | NAAA 4428/4885EPHX2 200/4885HTT 4106/4885 |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | SFN, CCNE2, MSMO1 | NAAA 4362/4885EPHX2 182/4885HTT 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.